$PFE Company News Acura Pharmaceuticals ends Pfizer

New Post Public Reply Private Reply Replies (0) Message Board

Apr 11, 2014 at 9:39 PM

$PFE Company News

Acura Pharmaceuticals ends Pfizer licensing pact 7:10 a.m. April 10, 2014 - MarketWatch.com
U.S. stocks fall; Nasdaq 3-day loss worst since 2011 4:48 p.m. April 7, 2014 - Victor Reklaitis
Newscast: Wall Street extends recent selloff 4:28 p.m. April 7, 2014 - MarketWatch
Tesla, Facebook seesaw; Questcor surges on deal 3:54 p.m. April 7, 2014 - Ben Eisen
Pfizer shares drop despite positive test for breast-cancer drug 1:03 p.m. April 7, 2014 - blogs.marketwatch.com
Pfizer drops 2.5% to lead Dow decliners 9:35 a.m. April 7, 2014 - William L. Watts
How sector stock funds can make your portfolio whole 7:01 a.m. April 7, 2014 - Jonathan Burton
Best, worst stocks of the $100 billion club: Morgan Stanley 2:03 p.m. March 31, 2014 - blogs.marketwatch.com
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. March 27, 2014 - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein

Acura Pharma Ends Agreement with Pfizer - Analyst Blog 5:35 p.m. Today - Zacks.com
FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon? 3:07 p.m. Today - TheStreet.com
3 Stocks Pushing The Drugs Industry Downward 1:02 p.m. Today - TheStreet.com
Dow 30 Stock Roundup: Pfizer Drug Trial Dents, P&G Ups Dividend - Analyst Blog 11:06 a.m. Today - Zacks.com
Nektar Presents Pipeline Data - Analyst Blog 5:10 p.m. April 10, 2014 - Zacks.com
Roche's Competitive Advantage 4:22 p.m. April 10, 2014 - Seeking Alpha
A Favorable Look at Pfizer and Signet 3:54 p.m. April 10, 2014 - Barrons.com
Investors: Brace for a Turbulent Second Quarter 1:07 p.m. April 10, 2014 - FOXBusiness
French plan to allow generics alarms Big Pharma 9:32 a.m. April 10, 2014 - Seeking Alpha
Pfizer Becomes #26 Most Shorted Dow Stock, Replacing Cisco Systems 9:20 a.m. April 10, 2014 - TheStreet.com
AVERSION licensing deal terminates 8:05 a.m. April 10, 2014 - Seeking Alpha
Podcast Patent Battle Roils Big And Small Media 5:22 p.m. April 9, 2014 - Investors Business Daily
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. April 9, 2014 - TheStreet.com
Teva to Launch Generic Lovaza - Analyst Blog 4:45 p.m. April 9, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: PFE, GE, MCD 2:44 p.m. April 9, 2014 - TheStreet.com
Dow Today: Pfizer (PFE) Lower 1:00 p.m. April 9, 2014 - TheStreet.com
Top 10 Net Payout Yield Stocks For April 2014 11:19 a.m. April 9, 2014 - Seeking Alpha
Pfizer: It Never Rains, It Pours 7:24 a.m. April 9, 2014 - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:31 a.m. April 9, 2014 - Seeking Alpha
Update on Merck's MK-3475 - Analyst Blog 6:35 p.m. April 8, 2014 - Zacks.com

Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest 10:14 a.m. Today - PR Newswire - PRF
Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts 9:00 a.m. Today - BusinessWire - BZX
Acura Pharmaceuticals Announces Return of Product Rights 6:15 a.m. April 10, 2014 - Marketwire
Thyroid Cancer Global Clinical Trials Review, H2, 2013 1:29 p.m. April 9, 2014 - PR Newswire - PRF
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma 8:00 a.m. April 9, 2014 - PR Newswire - PRF
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013 10:32 a.m. April 8, 2014 - PR Newswire - PRF
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept 8:00 a.m. April 7, 2014 - PR Newswire - PRF
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer 10:30 a.m. April 6, 2014 - BusinessWire - BZX
AMCP Foundation Launches Initiative to Identify Emerging Medication Management Practices that Can Advance Patient Care and Outcomes; Project Supported by Pfizer 12:38 p.m. April 3, 2014 - PR Newswire - PRF
Exosomes Shine a Light on Alzheimer's Disease and CTE 10:16 a.m. April 3, 2014 - ACCESSWIRE
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool 2:30 p.m. April 1, 2014 - PR Newswire - PRF
LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR 6:26 p.m. March 28, 2014 - BusinessWire - BZX
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices 11:31 a.m. March 28, 2014 - PR Newswire - PRF
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan 8:00 a.m. March 28, 2014 - PR Newswire - PRF
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. March 27, 2014 - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...